The global influenza medication market is primarily driven by annual epidemic outbreak in developed countries such as the U.S. and flu outbreaks in several regions across the globe.
The global influenza medication market is primarily driven by annual epidemic outbreak in developed countries such as the U.S. and flu outbreaks in several regions across the globe.
As per a report published by Centers for Disease Control and Prevention (CDC), in October 2019, 9.7 million cases of influenza had been reported in the U.S. in that particular year.
Global influenza medication market include application of seasonal vaccines. However, in several cases, the flu vaccines may not be efficient for prevention.
The influenza medication market is influenced by several drivers and trends. These factor may bring momentum to demand rate for influenza (flu) antiviral drugs.
Request Brochure of Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=24038
Further, rising awareness regarding serious impacts of influenza is one of the key driving factors driving growth of the global influenza medication market. Impact of influenza on human health may result in some other critical diseases.
On other hand, current lifestyle trends may result in development of influenza in significant proportion of the global population. This may emerge as one of most common contagious diseases.
Pregnant women, geriatric population, and people with weak autoimmune system are at high risk of developing influenza. The genetic mutation nature of the virus impels them to undergo consistent change. This has adverse effect on human immunity. This has resulted in research and development of novel therapeutics method and introduction of new influenza medications. This, in turn, is likely to fuel the influenza drugs market.
Moreover, increasing healthcare expenditure and investment in research and development activities are likely to accelerate growth rate of the global influenza medication market. However, adoption of influenza vaccines is interfering with growth of the market.
Request for Analysis of COVID19 Impact on Influenza Medication Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=24038
Global Influenza Medication Market: Snapshot
Influenza medication includes antiviral drugs prescribed for the treatment of influenza. Influenza, also known as flu, is a respiratory disease caused by an influenza virus. It is a viral infectious disease that includes three major types: type A, type B, and type C. The common symptoms of the disorder are cold, cough, fever, and sore throat, which can be severe or mild. Seasonal outbreak of influenza primarily occurs in winter. Most people generally recover fully, but severe complications such as pneumonia can also develop. Initiation of antiviral treatment is recommended for hospitalized influenza patients. High growth of the global influenza medication market is due to unmet medical needs within the annual influenza epidemics along with strong R&D focus resulting in new and advanced treatments and drugs, and increasing demand due to government stockpiling.
Request for Custom Research: https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=24038
Based on Distribution Channel, Pharmacies Held Lead however Hospitals Likely to Show Lucrative Prospects
The global influenza medications market has been classified on the basis of three categories, which are by product, distribution channel, and geography (regions & countries). The product category is further sub segmented into zanamivir, oseltamivir, peramivir, amantadine, rimantadine, inosine and others including laninamivir octanoate. Of these, oseltamivir held lead with a share of 48.8% in the global market in 2016. The rising use of oseltamivir in the treatment of flu triggered by H1N1 virus and prophylaxis is one of the key reasons behind the segment’s lead.
In term of distribution channels, global influenza medications market is divided into hospitals, clinics, pharmacies and others. Incidence and prevalence of flu are gradually increasing across the globe. Of these, the pharmacies segment held dominance in 2016. Through the course of the forecast period, growth run witnessed by the segment is likely to remain steady due to the mushrooming pharmacy stores around the world. Besides this, the market is likely to witness lucrative prospects in the hospitals segment.
For instance, According to the CDC, around 5% to 20% of the population is affected with the flu in the U.S. each year. Additionally, an estimated 200,000 people are hospitalized due to flu infection in the U.S. each year; of these 36,000 die due to flu complications. Favorable policies for treatment and prevention of influenza by the government in developed regions. These are the major drivers in the growth of influenza medication market. The market in Asia Pacific is expected to expand at a high CAGR of 1.8% during the forecast period due to availability of low cost treatment and availability of better health care facilities. Patent expiry of key drugs and entry of generics and Side effects of anti-influenza drug therapy are the major restraining factors affecting Influenza medication market.
Buy Influenza Medication Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=24038<ype=S
US Emerged as Most Attractive Market for Influenza Medication in North America
By geography, global Influenza medication market has been segmented into major five regions: North America, Europe, Asia Pacific, Latin America and Middle East & Africa. In 2016, North America and Europe accounted for the largest share of the Influenza medication market followed by Asia, Latin America, and Middle East & Africa. The U.S. dominated the Influenza medication market in North America, accounting for around 49.8% share in 2016. North America leads the global market with a major contribution of the U.S. owing to increasing adoption of advanced and high-cost drug therapies, increased treatment rate, and favorable reimbursement policies in the country.
Europe and Asia Pacific are projected to be moderately lucrative markets from 2017 to 2025. Increase in the number of public awareness programs for prevention and diagnosis of chronic diseases such as influenza has significantly reduced the prevalence of influenza in Europe. In Europe, demand for influenza medication products is the maximum, with a major share held by the inosine product segment. Asia Pacific is expected to dominate the global market, due to major contribution from developing countries. China and India are highly populated countries with the maximum number of influenza patients making them major contributor to the growth of the market in Asia Pacific.
The key players operating in the global influenza medications market are Daiichi Sankyo Company, GlaxoSmithKline plc, Natco Pharma, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH (Novartis AG), Sun Pharmaceutical Industries Ltd. and Mylan, Inc. The global Influenza medication market is dominated only by few players that operates in global market.
Browse More Trending Reports by Transparency Market Research:
Dental Tweezers Market: https://www.transparencymarketresearch.com/dental-tweezers-market.html
Homecare Ventilator Market: https://www.transparencymarketresearch.com/homecare-ventilator-market.html
Defibrillator Pads Market: https://www.transparencymarketresearch.com/defibrillator-pads-market.html
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/